Shan Kuang
I joined the lab in the spring of 2021. With my background in cancer pharmacology and in cancer genomics I hope to identify a molecular vulnerability of metastatic prostate cancer. To do this, I study the differences between indolent and metastatic versions of prostate cancers from RapidCaP.
